EULAR 2021

Early detection of PsA & patient stratification

Update GRAPPA recommendations & axial PsA vs axSpA

Treatment decissions and therapeutic options in PsA

RA treatment - status and perspectives

Early detection and treatment of RA

Difficult to treat RA - hot topics and challenges

Switching of treatment from reference etanercept to sandoz etanercept biosimilar in patients with rheumatic diseases: Real-world interim data from the compact study

JAKi in real life!

Vitamin D level in response to biologics

RA activity and risk of complications after Arthroplasty

Recurrence of joint inflammation

Using anti-TNF to deliver corticosteroids to inflammatory cells

Clinical outcome after switching between IL-6 and JAK inhibitors

Interstitial lung disease in patients with RA

Risk of cardiovascular events and disease activity

Influence of comorbitidy on mortality

Passive smoking in childhood and adulthood increases risk of RA

Definition of difficult to treat rheumatoid arthritis

JAKi dans la vraie vie!

Vitamine D et réponse aux biomédicaments

Complications après arthroplastie selon l’activité du rhumatisme

Où les arthrites récidivent-elles?

Interstitiell lungesykdom hos pasienter med RA

Risiko for kardiovaskulære hendelser og sykdomsaktivitet

Påvirkning av komorbiditeter på mortalitet

El tabaquismo pasivo aumenta el riesgo de padecer una artritis reumatoide

Definición de artritis reumatoide difícil de tratar

Cardiovascular risk and metabolomic profiling in PsA

Deucravacitinib (TYK2 Inhibitor) in Psoriasis and Psoriatic Arthirtis

Secukinumab: Adherence in PsA and AS

Hyperuricemia: increased risk of severe PsA course

Power-Doppler ultrasound of the achilles tendon to differenciate exercise vs. inflammation

GRAPPA Recommendations 2021

Faeceal microbiota transplantation

Role of Sex and Weight on PsA

Kardiovaskuläres Risiko und metabolomisches Profil bei PsA

Deucravacitinib (TYK 2 Inhibitor) neu bei PsA und Psoriasis

Secukinumab: Adhärenz bei PsA and AS

Cave Hyperurikämie: Erhöhtes Risiko für schweren Verlauf

Power-Doppler-Sono AS: Differenzierung Belastung vs. Inflammation

GRAPPA Empfehlungen 2021

Rolle von Geschlecht und Gewicht

Do patients with axSpA help us?

Impact of sex on BASDAI scores

Radiographic progression in axSpA

Feasibilty of anti-TNF tapering in low disease activity: The SPACING trial

Non-radiographic or radiographic axial SpA - does it matter?

Impatto del sesso sugli score del BASDAI

¿Nos ayudan los pacientes con espondiloartritis axial?

fattibilità della riduzione del dosaggio degli anti-TNF in pazienti con AxSpA e bassa attività di malattia: il trial SPACING

Progresión radiográfica en espondiloartritis axial

Immunogenicity of mRNA-COVID-19 vaccine in patients with inflammatory rheumatic disease

COVID-19 outcome in inflammatory arthropathy patients

Rituximab and COVID-19 (Multicenter-Study)

COVID-19 Vaccination in patients with rheumatic disease

Rituximab and COVID-19 (Nat. French Registry Study)

Outcome of Covid-19 in Rheumatoid Arthritis under Advanced Therapy

Influence of TNF-Inhibition on COVID-19

Risk factors of COVID-19 course in SLE

Patientenumfrage während der Pandemie

SARS-CoV2-Impfung bei Rheumapatienten

Rituximab bei COVID-19 (franz. Registerdaten)

COVID-19 bei SLE

Immunogenicidad de la vacuna mRNA-COVID-19 en pacientes con enfermedades reumáticas inflamatorias

Rituximab bei COVID-19 (Multicenter-Studien)

Einfluss von TNF-Blockern auf COVID-19-Verlauf

Convincing Anifrolumab data on efficacy and drug tolerance

Combination of Belimumab and Rituximab is beneficial

New therapy for cutaneous manifestations

Kombination Belimumab und Retuximab vorteilhaft

Neue Therapie für kutane Manifestationen

Anifrolumab in Wirksamkeit und Verträglichkeit überzeugend

Ultrasound halo sign as a potential monitoring tool for patients with giant cell arteritis

Tocilizumab Monotherapy for Giant Cell Arteritis - the GUSTO trial

Efficcacy and Safety of TNF-α Blockers and Tocilizumab in Takayasu Arteritis

What is new in Giant Cell Arteritis?

Efficacia e sicurezza degli anti-TNF e del tocilizumab nella arterite di Takayasu

Monoterapia con tocilizumab nella arterite a cellule giganti – il trial GUSTO

Lung involvement: diagnostic work-up and  new treatment modalities

Fatigue in Arthritis, SpA & systemic rheumatic diseases

Therapeutic drug monitoring and immunogenicity

Risk factors for ADAb formation: Data from the NOR-DRUM A trial

Lyme disease: Myths and reality

Secukinumab in patients with rotator cuff tendinopathy

Therapeutic drug monitoring (TDM) og immunogenisitet

Factores de riesgo del desarrollo de anticuerpos anti-infliximab.: resultados del ensayo NOR-DRUM A

Co nowego w reumatologii dziecięcej

EULAR, najnowsze postępy w reumatologii